Published: 3 November 2020
Author(s): Marcello Di Nisio, Nicola Potere, Matteo Candeloro, Antonella Spacone, Leonardo Pieramati, Giovanna Ferrandu, Giulia Rizzo, Matteo La Vella, Silvio Di Carlo, Donatella Cibelli, Giustino Parruti, Marcel Levi, Ettore Porreca
Issue: January 2021
Section: Original article

A considerable proportion of patients with Coronavirus Disease 2019 (COVID-19) presents with a hypercoagulable state which may increase the risk of thromboembolic complications [1]. The most typical coagulation abnormalities reported in patients with COVID-19 are markedly elevated D-dimer levels, modest reductions in platelet count, and a small prolongation of the prothrombin time [1]. In severe cases, these coagulation changes may progress to disseminated intravascular coagulation, which is associated with a high mortality [2].

Newsletters

Stay informed on our latest news!